ADELE

The purpose of the study is to test whether the addition of an immunotherapy drug, called tislelizumab, to the standard of care treatment of high-risk endometrial cancer reduces the risk of the disease coming back, and to determine if the new course of therapy is well-tolerated by participants.

Category
Trial Status
Recruiting
Trial Phase
Phase 2 Drug Trial
Registry Listing
ERM Project ID
73612
Trial contact details
Contact Person
Caitlin Bennett
What you need to know

Who can take part?

Any patients who have been diagnosed with high-risk endometrial cancer who have received surgery for the condition, and also require radiation and then chemotherapy. This trial can only enrol patients who have surgery in the previous 8 weeks.

What is involved for you?

Patients have standard  treatment for their disease, and 2/3 of patients in the trial also receive an additional immunotherapy medication (tislelizumab). Standard of care chemotherapy involves attending the clinic every 3 weeks for chemotherapy for 4 cycles. For patients who are receiving the  additional immunotherapy medication (tislelizumab), you will need to continue to attend the clinic for an additional 8 cycles. While in the clinic you will have a physical assessment, blood collection and complete a quality of life survey. 

All research clinical trials news

Jan Mundt had just celebrated the birth of her first grandchild when she received a devastating cancer diagnosis. Despite having never smoked, Mrs Mundt was told a pain in her chest was being...

10

Jun

Clinical trials help gran defy terminal lung cancer diagnosis

A new diagnostic and treatment approach for bladder cancer will undergo a clinical trial in Queensland.

07

May

Technology shines a light on better bladder cancer detection

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

Displaying results 1-3 (of 20)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|